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Abstract
Accountable decision-makers are required to legitimize their priority setting decisions in health to members of 
society. In this perspective we stress the point that fair, legitimate processes should reflect efforts of authorities 
to treat all stakeholders as moral equals in terms of providing all people with well-justified, reasonable reasons to 
endorse the decisions. We argue there is a special moral concern for being accountable to those who are potentially 
adversely affected by decisions. Health authorities need to operationalize this requirement into real world action. 
In this perspective, we operationalize five key steps in doing so, in terms of (i) proactively identifying potentially 
adversely affected stakeholders; (ii) comprehensively including them in the decision-making process; (iii) ensuring 
meaningful participation; (iv) communication of recommendations or decisions; and (v) the organization of 
evaluation and appeal mechanisms. Health authorities are advised to use a checklist in the form of 29 reflective 
questions, aligned with these five key steps, to assist them in the practical organization of legitimate priority setting 
in healthcare.
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Introduction
Health authorities make priority setting decisions on behalf 
of society. Their decisions are bound to be controversial as 
stakeholders likely disagree over which priorities should be set 
and over who should benefit and who should not. Increasingly, 
there is attention for organizing ‘fair, legitimate decision-
making processes’ and organizing ‘public deliberation.’ In line 
with this trend, health authorities often organize some form 
of stakeholder participation, embedded in their decision-
making processes.1 In doing so they may use different 
deliberative methods, identified and described elsewhere.1,2 
Reasons for organizing stakeholder participation can be 
multiple, eg, gaining an understanding of the stakeholders’ 
values and how a specific decision affects these values, 
enhancing the epistemic outcome of deliberation, educating 
the public, or promoting democracy by making citizens co-
decision-makers.1-4 
Whatever the health authorities’ specific reason for organizing 
stakeholder participation, fair, legitimate processes have to 
reflect efforts of authorities to treat all stakeholders as moral 
equals and thus provide people with well-justified, reasonable 
reasons to endorse the process and thus the decision – even 
if it is the case that they would have preferred another 
outcome.5,6 This is especially relevant for stakeholders who 
carry the negative consequences of a decision, the so-called 
adversely affected stakeholders. 
In practice, health authorities lack easy-to-use tools that can 
support them in carefully organizing meaningful stakeholder 
participation. As such, there is a risk that participation of 
stakeholders, if organized at all, merely reflects tokenism 
rather than justified and adequately integrated participation. 
In response to this, we here present a checklist for carefully 
organizing stakeholder participation. This can help health 
authorities in being accountable for their priority setting 
decisions, especially towards adversely affected stakeholders.
Why Are Health Authorities Accountable to (Adversely 
Affected) Stakeholders?
Priority setting in health is recognized as a value-laden 
political process, which takes place in an environment of 
diverging social values and interests.7-13 Indeed, members of 
society, or stakeholders, may carry a wide range and diversity 
of social values, such as maximizing population health, doing 
no harm, avoiding catastrophic expenditure, or giving priority 
to the worse off.14-16 According to liberal theory, stakeholders 
may reasonably disagree on the relative importance of such 
values and as well on how some of them are specified during 
priority setting.17 
Health authorities make priority setting decisions on behalf 
of society, eg, when deciding on the public reimbursement of 
new health interventions. The power that health authorities 
possess to make priority setting decisions on behalf of 
societies, characterized by representing this value pluralism, 
is justified only in so far decision-making is carried out in 
legitimate ways.
Legitimate decision-making requires that processes reflect 
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efforts of authorities to treat all stakeholders as moral 
equals.5 Ideally, this means all stakeholders would have good 
reasons to endorse the decision-making process as fair - even 
those who would have preferred another outcome than the 
resulting decision.5,6 In order to enjoy the moral authority 
to make priority setting decisions in health (as opposed to 
some contingent social power), there is an ethical demand 
on health authorities to be accountable to adversely affected 
stakeholders.5 Independently of what kind of normative 
theory one endorses, it can be seen as a fundamental ethical 
requirement, that those who are carrying the burdens of the 
decisions are (i) explicitly recognized as being stakeholders; 
and (ii) entitled to being provided with good reasons to 
appreciate the decision-making process as fair. If these 
concerns are not taken seriously by decision-makers they lose 
their moral authority for making priority setting decisions in 
health. Subsequently, they may undermine the legitimacy of 
their own decision-making process.18 
Who Are the Adversely Affected Stakeholders?
We distinguish between four reasons why stakeholders can 
be considered adversely affected by decisions: (i) stakeholders 
experience a health loss as a direct result of a priority setting 
decision (the health loss reason); (ii) stakeholders experience 
a health loss as an indirect result of a priority decision, 
which is the case when a newly approved health intervention 
displaces their personally needed intervention (the indirect 
health loss reason); (iii) stakeholders need to communicate 
decisions which may adversely affect the patient-clinician 
relationship (the communication reason)19; (iv) stakeholders 
are responsible for implementing a decision they strongly 
disagree with (the integrity reason). This list is not necessarily 
exhaustive: further categories may be added according to a 
specific burden inflicted by a decision. 
 
Development of the Checklist
Important academic work on the conditions of fair processes 
is the accountability for reasonableness (A4R) framework.10,20 
This framework identifies four key conditions for organizing 
fair processes: (i) organizing deliberation among stakeholders 
to identify relevant rationales; (ii) ensuring transparency of 
the decisions; (iii) organization  of appeal opportunities; and 
(iv) regulation of conditions i-iii.10,20 However, there is a gap 
in the literature on how to comprehensively translate these 
requirements into practice in general,21 and more specifically 
when it comes to ensuring accountability towards the 
adversely affected identified above.5
We developed a checklist by operationalizing the A4R 
framework and reflecting on the ethical notions it invokes, 
supported by broader literature on stakeholder participation 
and public deliberation, paying special concern for the 
ethical demand to be accountable to adversely affected 
stakeholders.2-5,20,22-27 Based on this reflection we defined five 
key actionable steps in being accountable to adversely affected 
stakeholders: (i) proactively identifying potentially adversely 
affected stakeholders; (ii) comprehensively including 
stakeholders; (iii) ensuring meaningful participation; (iv) 
communication of recommendations and/or decisions; and 
(v) the organization of evaluation and appeal mechanisms 
– further explained below. In doing so, we did not assume a 
generic model of decision-making, as real-world decision-
making processes are unlikely to take place in a chronological 
and tidy manner. Further reflection on what it would entail 
to actually operationalize these five steps was carried out in 
accordance with the underlying imperative of treating people 
as moral equals. A simple test of whether the inclusion of 
stakeholders meets this imperative or not, is to imagine 
whether we would have felt respectfully recognized and 
properly involved on the suggested terms ourselves. By 
following this methodology we could spell out questions that 
health authorities should think about when they organize 
stakeholder participation. This reflection process resulted in 
a shortlist of questions for use by health authorities. The five 
steps and their respective questions are together presented as 
a reflective checklist (Box 1). The checklist is not meant to be 
all-encompassing or exhaustive, rather, it is meant to cover key 
concerns and invoke reflection by health authorities on the 
most relevant and actionable choices they make. Therefore, 
the checklist should be taken as a starting point for discussion 
and future adjustment.
Step 1: Identifying Potentially Adversely Affected Stakeholders
Authorities must make efforts to systematically identify 
potentially adversely affected stakeholders before making 
a decision, as to ensure that stakeholders’ perspectives, 
suggestions and arguments will enter into the decision-
making process, preferably as early as possible during the 
deliberative process.5 The first step is to identify real world 
persons as representatives of the potentially adversely affected 
stakeholders according to the categories we identified above. 
Step 2: Including Stakeholders in the Decision-Making Process
Identified stakeholders must be included in the decision-
making process.4,5,22 This demands a pro-active attitude of 
health authorities, which starts with inviting stakeholders 
to attend meetings and ensuring meetings are accessible.22-24 
Specifically, efforts should be made to ensure that known 
hard-to-reach stakeholders actually have reasonable 
opportunities to participate.24 Alternatively, strategies 
for including stakeholders values, other than their direct 
participation, should be explored pro-actively to ensure the 
uptake of arguments – in line with broader consultation and 
communication efforts as defined elsewhere.2,5
 
Step 3: Ensuring Meaningful Participation
Efforts must be made to ensure meaningful participation. 
This requires that stakeholders can actively interact in 
the deliberation, freely voice their perspectives and that 
they are treated with due respect – while being provided 
with sufficient time to do so.3,5,11,22,23,25 Also, it requires that 
further evidence is considered or commissioned when this 
is feasible. Furthermore, all evidence and argumentation 
put forward should be presented to stakeholders in time and 
carefully addressed in a way that is understandable to all 
stakeholders.5,22,25 Importantly, this requires that their input is 
considered, put to use, scrutinized and not ignored – and that 
its clear at the outset of a process, to all stakeholders involved, 
how divergent views and interests are to be resolved and this 
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concern is to be satisfied.5 Overall, the deliberative process 
should provide opportunities for mutual learning.3,5,23,26,27
 
Step 4: Communicating Recommendations and/or Decisions 
in Understandable and Transparent Ways
The final recommendations and/or decisions have to be 
determined by acceptable standards of voting or left to 
the discretion of legitimately appointed decision-makers. 
Decisions should be communicated shortly after being made, 
in transparent ways that help shape understanding among 
stakeholders of why the specific decision was made.4,5 In doing 
so, health authorities should provide clear argumentation for 
why those who become adversely affected by their decision 
are to carry the burden.5
Step 5: Organizing Evaluation and Appeal Options
User-friendly evaluation and appeal options should be 
organized.4,10 Any appeals made should be documented 
and made anonymous and publicly available. Moreover, 
mechanisms should be put in place that ensure all appeals 
are handled with care – providing justification of the appeals 
outcome by decision-makers in an understandable way.5
How to Use the Checklist?
Health authorities can use the checklist to revise for possible 
shortcomings of current processes and install mechanisms 
for improvement. As mentioned, the checklist is generic in 
nature and questions included in the checklist are relevant to 
reflect on throughout a decision-making process. In practice, 
processes may be split-up into specific steps (eg,  assessment 
and appraisal) for which certain questions may be more (or 
less) relevant to consider. Also, if decision-making is split-up 
into separate steps, it may well be that each step requires a 
different answer to the same question. Furthermore, answers 
to questions are context-specific and there is no decisive 
evidence on what would constitute ‘right answers’ to these 
individual questions. In some contexts it may eg, be reasonable 
to reimburse travel expenses for the sake of accessibility, while 
in other cases this may be judged irrelevant or inappropriate. 
Nevertheless, health authorities are advised to inform their 
specific choices by evidence if available – or to learn from 
other countries’ experiences. Finally, the checklist reflects an 
aspirational goal of ideal accountability of decision-makers 
to adversely affected stakeholders. Authorities should take 
incremental steps towards meeting this goal by prioritizing 
Box 1. A Checklist for Stakeholder Participation
A. Identification of potentially adversely affected stakeholders
1. Who may experience a health loss as a result of a negative decision?
2. Who may experience a health loss as a result of a positive decision?
3. Who may be adversely affected because they are responsible for communicating the decision?
4. Who may be adversely affected because they are responsible for implementing the decision?
B. Comprehensive stakeholder inclusion
1. Are all relevant stakeholders informed about the possibility and procedures of participation?
2. Is participation organized in a way that effectively and efficiently facilitates the inclusion of stakeholders?
3. Are efforts made to include all relevant, especially difficult-to-reach, stakeholders?
4. Can stakeholders participate in the identification and topic selection of health services for evaluation?
5. Can stakeholders participate in the scoping of relevant questions for evaluation?
6. Can stakeholders participate in the development of recommendations?
7. Can stakeholders participate in the evaluation of decisions?
8. Are alternative non-participatory strategies used for inclusion of stakeholders’ values?
C. Meaningful stakeholder participation 
1. Are stakeholders fully and in time informed about the available evidence?
2. Is argumentation and evidence presented in a way that is understandable to all relevant stakeholders? 
3. Can stakeholders freely voice their perspectives (ie, no stakeholder is allowed to dominate a discussion or activity)?
4. Are stakeholder perspectives addressed in respectful and courteous ways?
5. Do stakeholders have sufficient time to provide input? 
6. Are stakeholder perspectives equally accounted for in the deliberation?
7. Is it clear to all stakeholders involved how their input is going to be considered, scrutinized and put to use?
8. Can stakeholders actively interact in the deliberation?
9. Is further evidence collection considered when judged relevant and feasible?  
D. Transparent communication of recommendations and/or decisions 
1. Is information provided on the underlying argumentation and process to come to a recommendation and/or decision?
2. Is input from stakeholders documented and addressed explicitly?
3. Are recommendations and/or decisions clearly communicated? 
4. Are stakeholders informed in time on the recommendation and/or decision?
E. Appeal and evaluation
1. Can stakeholders easily make an appeal on the underlying argumentation or process? 
2. Are appeals documented and publicly accessible?
3. Are appeals handled consistently and is justification provided in an understandable way?
4. Are mechanisms in place to revise decisions or the process based on appeals?
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specific efforts according to local needs and affordances. 
Conclusion
Accountable decision-makers are required to legitimize their 
priority setting decisions in health to members of society. 
Health authorities need to operationalize this requirement 
into real world action. In this perspective, we have argued 
for five key steps in doing so, in terms of proactively 
identifying potentially adversely affected stakeholders, 
comprehensively including them in the decision-making 
process, ensuring meaningful participation, communication 
of recommendations or decisions, and the organization 
of evaluation and appeal mechanisms. Health authorities 
are advised to use the provided checklist in the form of 29 
reflective questions to assist them in the practical organization 
of legitimate priority setting in healthcare.
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